ADMA Biologics (ADMA) vs. Its Peers Head to Head Survey

ADMA Biologics (NASDAQ: ADMA) is one of 287 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its competitors? We will compare ADMA Biologics to related companies based on the strength of its analyst recommendations, profitability, risk, earnings, dividends, valuation and institutional ownership.

Risk and Volatility

ADMA Biologics has a beta of 2.5, indicating that its share price is 150% more volatile than the S&P 500. Comparatively, ADMA Biologics’ competitors have a beta of 2.38, indicating that their average share price is 138% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for ADMA Biologics and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ADMA Biologics 0 0 2 0 3.00
ADMA Biologics Competitors 925 3347 11855 237 2.70

ADMA Biologics presently has a consensus target price of $6.50, suggesting a potential upside of 101.24%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 41.08%. Given ADMA Biologics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe ADMA Biologics is more favorable than its competitors.

Insider and Institutional Ownership

32.8% of ADMA Biologics shares are held by institutional investors. Comparatively, 49.7% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 60.4% of ADMA Biologics shares are held by insiders. Comparatively, 17.5% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares ADMA Biologics and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
ADMA Biologics $10.66 million -$19.51 million -3.94
ADMA Biologics Competitors $290.27 million $35.99 million 58.36

ADMA Biologics’ competitors have higher revenue and earnings than ADMA Biologics. ADMA Biologics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares ADMA Biologics and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ADMA Biologics -35.00% -76.26% -9.77%
ADMA Biologics Competitors -5,441.68% -162.70% -35.92%

Summary

ADMA Biologics beats its competitors on 8 of the 13 factors compared.

ADMA Biologics Company Profile

ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.